Company / Operating Income
Monte Rosa Therapeutics, Inc. Operating Income History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$81.1M
FY2024
5-year range
-$143.3M / -$28.0M
FY2020-FY2024
Trend
+43.4%
vs FY2023
Sector context
#82 of 204
Health Care
What the data says
At -$81M, Monte Rosa Therapeutics, Inc.'s operating income ranks #82 of 204 in the Health Care sector. Operating Income returned to growth in FY2024 after 3 years of decline, reaching -$81M.
Based on SEC 10-K filings.
-$81M in FY2024.
Improved from -$112M to -$81M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#82 of 204 in Health CareTop 40% of 204This company -$81.1M Sector average $107.7M
▼
-175.3% below sector average
Key checks
Key Insights
- In FY2024, operating income increased 43.4% year-over-year.
- Ranks #82 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2020.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$81.1M | +43.4% |
| FY2023 | -$143.3M | -27.5% |
| FY2022 | -$112.4M | -54.2% |
| FY2021 | -$72.9M | -160.2% |
| FY2020 | -$28.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026